Similar articles

• Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.

  Ottoboni T, Lauw M, Keller MR, Cravets M, Manhard K, Clendeninn N, Quart B. Ottoboni T, et al. Future Oncol. 2018 Nov;14(27):2849-2859. doi: 10.2217/fon-2018-0311. Epub 2018 Jun 6. Future Oncol. 2018. PMID: 29873529 Clinical Trial.
• The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.

  Navari RM. Navari RM. Expert Opin Drug Saf. 2019 Dec;18(12):1127-1132. doi: 10.1080/14740338.2019.1682547. Epub 2019 Oct 22. Expert Opin Drug Saf. 2019. PMID: 31622113
• Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.

  Navari RM. Navari RM. Expert Opin Drug Saf. 2020 Feb;19(2):205-210. doi: 10.1080/14740338.2020.1691521. Epub 2019 Nov 14. Expert Opin Drug Saf. 2020. PMID: 31709853
• Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.

  Rapoport B, Smit T. Rapoport B, et al. Expert Opin Drug Saf. 2017 Jun;16(6):697-710. doi: 10.1080/14740338.2017.1325868. Expert Opin Drug Saf. 2017. PMID: 28460548 Review.
• Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK₁) receptor antagonists.

  Bošnjak SM, Gralla RJ, Schwartzberg L. Bošnjak SM, et al. Support Care Cancer. 2017 May;25(5):1661-1671. doi: 10.1007/s00520-017-3585-z. Epub 2017 Jan 20. Support Care Cancer. 2017. PMID: 28108820 Free PMC article. Review.